Compare Citius Pharmaceuticals Inc (CTXR) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs VF Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while VF Corp trades at $14.66 (market cap $5.71B). The key difference: VF Corp is far larger — about 419.2× Citius Pharmaceuticals Inc's market cap, and VF Corp pays a 2.48% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and VF Corp for 64 Days on average.
| CTXR | VFC | |
|---|---|---|
Market Cap | $13.62M | $5.71B |
Volume | 132,438 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $21.55 |
52-Week Low | $0.48 | $12.62 |
Typical Hold Time | 16 Days | 64 Days |
Enterprise Value | $3.79M | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
VFC trades at $14.38, down 0.48% with a bullish technical signal from moving averages. The company shows mixed fundamentals with revenue declining from $11.8B in 2022 to $9.5B in 2025, while profitability remains challenged with negative net income of -$189.72M. Recent earnings show volatility with one beat and two misses in the last four quarters. The stock trades at attractive valuation multiples with P/E of 21.06 and P/S of 0.61, below industry averages.
VFC presents a turnaround opportunity with discounted valuation and improving cash flow projections for 2026, but faces significant execution risks from Vans brand weakness and ongoing debt reduction challenges. Analyst consensus leans neutral with 52% hold rating and $18.33 price target suggesting 27% upside potential, though recent dividend cuts and brand-specific headwinds require careful monitoring of Q3 earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
